OmniAb Inc. has released a new corporate presentation outlining its proprietary discovery technology platform, which is licensed worldwide to support the development of innovative therapeutics. The presentation highlights the company’s technology offerings across multiple modalities, including antibody discovery, multispecifics, CAR-T binders, radiopharmaceuticals, and peptides. OmniAb emphasizes the scalability and proven success of its technologies, supported by a network of over 100 partners. The document notes a growing demand for discovery technologies in the pharmaceutical industry, driven by higher regulatory approval success rates for antibody therapeutics compared to small molecules. Industry trends, such as regulatory changes under the Inflation Reduction Act, are also discussed as factors influencing increased investment in antibody-based drug development. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief on January 11, 2026, and is solely responsible for the information contained therein.